Ｍ－ＳＯＳＥＩ（4565）　First Subject Dosed in Phase1 Clinical Study of Novel Selective Muscarinic M4 Agonist in Development to Treat Major Symptoms of Alzheimer’s Disease 2017/09/01
/-
読み込み中…